Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 64

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 64
---
 adversely affect the combined company’s operations, including the ability to maintain relationships with customers and employees prior to, or after, the Transactions or to achieve the anticipated benefits of the Transactions. The combined company may not be able to retain Clearwater and Enfusion’s existing customers, which could have an adverse effect on the combined company’s business and operations, and third parties may terminate or alter existing contracts or relationships with Clearwater or Enfusion. As a result of the Transactions, the combined company may experience impacts on relationships with customers that may harm the combined company’s business, financial position, results of operations and cash flows. Certain customers may seek to terminate or modify contractual obligations following the Transactions, whether or not contractual rights are triggered as a result of the Transactions. There can be no guarantee that customers will remain with or continue to have a relationship with the combined company or do so on the same or similar contractual terms following the Transactions. If any customers seek to terminate or modify contractual obligations or discontinue the relationship with the combined company, then the combined company’s business, financial position, results of operations and cash flows may be harmed. 38

Clearwater and Enfusion also have contracts with suppliers, licensors and other business
partners which may require Clearwater or Enfusion, as applicable, to obtain consent from these other parties in connection with the Transactions, or which may otherwise contain limitations applicable to such contracts following the Transactions. If
these consents cannot be obtained, the combined company may suffer a loss of potential future revenue, incur costs and lose rights that may be material to the combined company’s business. In addition, third parties with whom Clearwater or
Enfusion currently have relationships may terminate or otherwise reduce the scope of their relationship with either party in anticipation of the Transactions. Any such disruptions could limit the combined company’s ability to achieve the
anticipated benefits of the Transactions. The adverse effect of any such disruptions could also be exacerbated by a delay in the completion of the Transactions or by a termination of the Merger Agreement.

The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company’s business, financial position, results of operations and cash flows.

The combined company may be exposed to increased litigation from stockholders,
customers, suppliers and other third parties due to the combination of Clearwater’s and Enfusion’s businesses following the Transactions. Such litigation may have an adverse impact on the combined company’s business, financial
position, results of operations and cash flows, or may cause disruptions to the combined company’s operations.